Astellas Vascular Sutton's new drug Fezolinetant has been approved for clinical use in China.

Vascular sulphation (VMS), i.e. hot flashes and night sweats in post-menopoly women.
it is estimated that about 57 per cent of women aged 40 to 64 worldwide experience symptoms of hot flashes and night sweats, which tend to cause anxiety, irritability, reduced productivity and depression, which can greatly affect women's sleep and quality of life.
Fezolinetant is an oral non-hormonal compound developed by Ogeda that normalizes the activity of KNDy neurons by blocking the signaling of neuroglytic peptide B (NKB), thus regulating the body temperature regulation center and reducing the frequency and severity of hot flashes.
2017, Astellas bought Ogeda for 500 million euros ($534 million) to get the drug.
The results of the phase IIb dose study of fezolinetant for the treatment of vascular sulphation, published at the 2019 Annual Meeting of the American Endocrinology Association (ENDO), showed that the average change in frequency and severity of FEzolinetant vs. moderate to severe VMS in the placebo group was statistically significant in weeks 4 and 12 of treatment.
safety, the rates of adverse events in each group of treatments were similar, mostly mild or moderate, with no deaths or serious adverse events associated with treatment.
.